Last reviewed · How we verify
NCT06404515
Telehealth Group Counseling and Preventive Care for Women
NA trial testing Telehealth Group Counseling in ASCVD in 13 participants. Completed in 14 November 2024.
14 November 2024
Quick facts
| Lead sponsor | Weill Medical College of Cornell University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 13 |
| Start date | 10 July 2024 |
| Primary completion | 14 November 2024 |
| Estimated completion | 14 November 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Telehealth Group Counseling
Conditions studied
- ASCVD — all drugs for ASCVD →
- NSTEMI — all drugs for NSTEMI →
- STEMI — all drugs for STEMI →
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Weill Medical College of Cornell University
Who can join
18 and older, female only, with ASCVD or NSTEMI. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to utilize an innovative healthcare delivery strategy via telehealth group counseling sessions to improve engagement, adherence, and ultimately outcomes in female patients with atherosclerotic cardiovascular disease (ASCVD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06404515
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ASCVD
Currently open trials in the same condition.
- NCT06691217 — Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis · Phase 2 · recruiting
- NCT07417618 — INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) · active not recruiting
- NCT07270887 — The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks · recruiting
- NCT06551701 — ACHIEVE Pilot Statins for Vascular Protection · active not recruiting
- NCT06767774 — Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus · Phase 4 · recruiting
Other Weill Medical College of Cornell University trials
Trials by the same sponsor.
- NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
- NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
- NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06404515 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
- Last refreshed: 24 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06404515.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing